AtaiBeckley (ATAI) Non-Current Deferred Tax Liability (2022 - 2025)

AtaiBeckley (ATAI) posted Non-Current Deferred Tax Liability of $12.0 million for Q4 2022.

Analysis

AtaiBeckley (ATAI) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends

AtaiBeckley's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $17.8 million for Q4 2025.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $12.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $12.0 million (changed N/A YoY) and the FY2022 annual result came in at $12.0 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability for Q4 2025 stood at $17.8 million, up from $6.9 million in the prior quarter.
The five-year high for Non-Current Deferred Tax Liability was $17.8 million in Q4 2025, with the low at $6.9 million in Q4 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	AtaiBeckley	1.61 Bn	1.61 Bn	-

Historic Data

Download Data